{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:01:20Z","timestamp":1791388880988,"version":"4.3.3"},"reference-count":383,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013284","name":"Program for Jilin University Science and Technology Innovative Research Team","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy that affects multiple systems including the muscle and heart. The mutant CTG expansion at the 3\u2032-UTR of the <jats:italic>DMPK<\/jats:italic> gene causes the expression of toxic RNA that aggregate as nuclear foci. The foci then interfere with RNA-binding proteins, affecting hundreds of mis-spliced effector genes, leading to aberrant alternative splicing and loss of effector gene product functions, ultimately resulting in systemic disorders. In recent years, increasing clinical, imaging, and pathological evidence have indicated that DM1, though to a lesser extent, could also be recognized as true brain diseases, with more and more researchers dedicating to develop novel therapeutic tools dealing with it. In this review, we summarize the current advances in the pathogenesis and pathology of central nervous system (CNS) deficits in DM1, intervention measures currently being investigated are also highlighted, aiming to promote novel and cutting-edge therapeutic investigations.<\/jats:p>","DOI":"10.3389\/fnagi.2021.755392","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T06:59:42Z","timestamp":1636959582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1"],"prefix":"10.3389","volume":"13","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Ni","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archneur.56.3.325","article-title":"Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy.","volume":"56","author":"Akiguchi","year":"1999","journal-title":"Arch. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jconrel.2021.06.007","article-title":"Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2.","volume":"335","author":"Akita","year":"2021","journal-title":"J. Control. Release"},{"key":"B3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jnci\/djy131","article-title":"Combining tumor microenvironment modulating nanoparticles with doxorubicin to enhance chemotherapeutic efficacy and boost antitumor immunity.","volume":"111","author":"Amini","year":"2019","journal-title":"J. Natl. Cancer Institute"},{"key":"B4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1017\/S1355617713000337","article-title":"Leader of the pack - neuropsychological assessment, 5th Edition, Muriel Lezak, Diane B. Howieson, Erin D. Bigler, & Daniel Tranel.","volume":"19","author":"Anderson","year":"2013","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/jcp.22842","article-title":"Tau splicing and the intricacies of dementia.","volume":"227","author":"Andreadis","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/pharmaceutics13020278","article-title":"Nanomedicine for gene delivery and drug repurposing in the treatment of muscular dystrophies.","volume":"13","author":"Andreana","year":"2021","journal-title":"Pharmaceutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.nmd.2007.02.012","article-title":"Cognitive profile in childhood myotonic dystrophy type 1: is there a global impairment?","volume":"17","author":"Angeard","year":"2007","journal-title":"Neuromusc. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.nmd.2011.04.009","article-title":"A new window on neurocognitive dysfunction in the childhood form of myotonic dystrophy type 1 (DM1).","volume":"21","author":"Angeard","year":"2011","journal-title":"Neuromusc. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acschembio.0c00036","article-title":"Precise targeted cleavage of a r(CUG) repeat expansion in cells by using a small-molecule-deglycobleomycin conjugate.","volume":"15","author":"Angelbello","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7799","DOI":"10.1073\/pnas.1901484116","article-title":"Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.","volume":"116","author":"Angelbello","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1756286419845567","DOI":"10.1177\/1756286419845567","article-title":"Advances in imaging of brain abnormalities in neuromuscular disease.","volume":"12","author":"Angelini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.4081\/ejtm.2019.9032","article-title":"Neuromuscular diseases and Covid-19: advices from scientific societies and early observations in Italy.","volume":"30","author":"Angelini","year":"2020","journal-title":"Eur. J. Transl. Myol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/j.nmd.2012.10.010","article-title":"Fatigue in muscular dystrophies.","volume":"22","author":"Angelini","year":"2012","journal-title":"Neuromusc. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"Cd003218","DOI":"10.1002\/14651858.cd003218","article-title":"Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.","volume":"4","author":"Annane","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1136\/jnnp.2003.032417","article-title":"Cerebral atrophy in myotonic dystrophy: a voxel based morphometric study.","volume":"75","author":"Antonini","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2004-07-2908","article-title":"Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.","volume":"105","author":"Arruda","year":"2005","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.nmd.2013.01.003","article-title":"Illuminating CNS and cognitive issues in myotonic dystrophy: workshop report.","volume":"23","author":"Axford","year":"2013","journal-title":"Neuromusc. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/biom11020159","article-title":"Transcriptome analysis reveals altered inflammatory pathway in an inducible glial cell model of myotonic dystrophy type 1.","volume":"11","author":"Azotla-Vilchis","year":"2021","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9498","DOI":"10.1021\/jacs.6b03697","article-title":"Integrating display and delivery functionality with a cell penetrating peptide mimic as a scaffold for intracellular multivalent multitargeting.","volume":"138","author":"Bai","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1971400916678223","article-title":"MRI findings and cognitive functions in a small cohort of myotonic dystrophy type 1: retrospective analyses.","volume":"30","author":"Bajrami","year":"2017","journal-title":"Neuroradiol. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nicl.2016.06.011","article-title":"Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1.","volume":"12","author":"Baldanzi","year":"","journal-title":"Neuroimage Clin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-016-0417-z","article-title":"Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study.","volume":"11","author":"Baldanzi","year":"","journal-title":"Orphanet J. Rare Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"25203","DOI":"10.1073\/pnas.1820297116","article-title":"Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.","volume":"116","author":"Bargiela","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial.","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molcel.2014.08.027","article-title":"Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease.","volume":"56","author":"Batra","year":"2014","journal-title":"Mol. Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"899.e10","DOI":"10.1016\/j.cell.2017.07.010","article-title":"Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9.","volume":"170","author":"Batra","year":"2017","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","article-title":"Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.","volume":"18","author":"Baughan","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/14734220600724569","article-title":"Interactions between Purkinje neurones and Bergmann glia.","volume":"5","author":"Bellamy","year":"2006","journal-title":"Cerebellum"},{"key":"B29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs.","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ane.12356","article-title":"Psychological characteristics of patients with myotonic dystrophy type 1.","volume":"132","author":"Bertrand","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"B32","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1172\/jci5346","article-title":"DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model.","volume":"103","author":"Berul","year":"1999","journal-title":"J. Clin. Investig."},{"key":"B33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1023\/a:1009842114968","article-title":"Progressive atrioventricular conduction block in a mouse myotonic dystrophy model.","volume":"4","author":"Berul","year":"2000","journal-title":"J. Intervent. Cardiac Electrophysiol."},{"key":"B34","article-title":"Myotonic dystrophy type 1","author":"Bird","year":"1993","journal-title":"Genereviews((r))"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1093\/hmg\/ddv219","article-title":"Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.","volume":"24","author":"Bisset","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.addr.2015.02.008","article-title":"Delivery of therapeutic oligonucleotides with cell penetrating peptides.","volume":"87","author":"Boisgu\u00e9rin","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2217\/epi-2020-0328","article-title":"DNA methylation at the DMPK gene locus is associated with cognitive functions in myotonic dystrophy type 1.","volume":"12","author":"Breton","year":"2020","journal-title":"Epigenomics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1172\/jci89616","article-title":"Targeting deregulated AMPK\/mTORC1 pathways improves muscle function in myotonic dystrophy type I.","volume":"127","author":"Brockhoff","year":"2017","journal-title":"J. Clin. Investig."},{"key":"B39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member.","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00234-020-02611-9","article-title":"Longitudinal study in patients with myotonic dystrophy type 1: correlation of brain MRI abnormalities with cognitive performances.","volume":"63","author":"Cabada","year":"2020","journal-title":"Neuroradiology"},{"key":"B41","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00234-020-02611-9","article-title":"Longitudinal study in patients with myotonic dystrophy type 1: correlation of brain MRI abnormalities with cognitive performances.","volume":"63","author":"Cabada","year":"2021","journal-title":"Neuroradiology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/arclin\/acx008","article-title":"Brain involvement in myotonic dystrophy type 1: a morphometric and diffusion tensor imaging study with neuropsychological correlation.","volume":"32","author":"Cabada","year":"2017","journal-title":"Arch. Clin. Neuropsychol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fnmol.2013.00057","article-title":"Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.","volume":"6","author":"Caillet-Boudin","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.bbadis.2014.01.004","article-title":"Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.","volume":"1842","author":"Carpentier","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddw266","article-title":"Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.","volume":"25","author":"Carrell","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e104697","DOI":"10.1371\/journal.pone.0104697","article-title":"Cognitive impairment in myotonic dystrophy type 1 is associated with white matter damage.","volume":"9","author":"Caso","year":"2014","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"36230","DOI":"10.1038\/srep36230","article-title":"Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila.","volume":"6","author":"Cerro-Herreros","year":"2016","journal-title":"Sci. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.omtn.2020.07.021","article-title":"Therapeutic potential of AntagomiR-23b for treating myotonic dystrophy.","volume":"21","author":"Cerro-Herreros","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","article-title":"miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.","volume":"9","author":"Cerro-Herreros","year":"2018","journal-title":"Nat. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"dmm032557","DOI":"10.1242\/dmm.032557","article-title":"Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.","volume":"11","author":"Chakraborty","year":"2018","journal-title":"Dis. Models Mech."},{"key":"B51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/archneur.55.3.305","article-title":"Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats.","volume":"55","author":"Chang","year":"1998","journal-title":"Arch. Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.neuron.2012.05.029","article-title":"Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy.","volume":"75","author":"Charizanis","year":"2012","journal-title":"Neuron"},{"key":"B53","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/dvdy.24240","article-title":"Developmental insights into the pathology of and therapeutic strategies for DM1: back to the basics.","volume":"244","author":"Chau","year":"2015","journal-title":"Dev. Dyn."},{"key":"B54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nbd.2018.01.003","article-title":"Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy.","volume":"112","author":"Chen","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"25317","DOI":"10.1038\/srep25317","article-title":"Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/ncomms3044","article-title":"Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.","volume":"4","author":"Childs-Disney","year":"2013","journal-title":"Nat. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/wnl.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/1533317513494453","article-title":"Reduced orexin-A levels in frontotemporal dementia: possible association with sleep disturbance.","volume":"28","author":"\u00c7oban","year":"2013","journal-title":"Am. J. Alzheimers Dis. Dement."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1590\/0001-3765201520140508","article-title":"Neurotrophins, cytokines, oxidative parameters and funcionality in progressive muscular dystrophies.","volume":"87","author":"Comim","year":"2015","journal-title":"Anais Acad. Bras. Ciencias"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/wrna.1398","article-title":"Developmental regulation of RNA processing by Rbfox proteins.","volume":"8","author":"Conboy","year":"2017","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1971400915621325","article-title":"Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: a longitudinal case series study.","volume":"29","author":"Conforti","year":"2016","journal-title":"Neuroradiol. J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1021\/cb400431f","article-title":"Reducing levels of toxic RNA with small molecules.","volume":"8","author":"Coonrod","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0022-510x(73)90095-6","article-title":"Cytoplasmic inclusion bodies within neurons of the thalamus in myotonic dystrophy. A light and electron microscope study.","volume":"19","author":"Culebras","year":"1973","journal-title":"J. Neurol. Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.3390\/ijms20184385","article-title":"An overview of circular RNAs and their implications in myotonic dystrophy.","volume":"20","author":"Czubak","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fgene.2019.00649","article-title":"Global increase in circular RNA levels in myotonic dystrophy.","volume":"10","author":"Czubak","year":"","journal-title":"Front. Genet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000478049","article-title":"Insulin signaling deficiency produces immobility in caenorhabditis elegans that models diminished motivation states in man and responds to antidepressants.","volume":"3","author":"Dagenhardt","year":"2017","journal-title":"Mol. Neuropsychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/gt.2008.69","article-title":"AAV vectors for RNA-based modulation of gene expression.","volume":"15","author":"Danos","year":"2008","journal-title":"Gene Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/wrna.107","article-title":"The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins.","volume":"3","author":"Dasgupta","year":"2012","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B69","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification.","volume":"172","author":"De Antonio","year":"2016","journal-title":"Revue Neurol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jnr.21377","article-title":"Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.","volume":"86","author":"de Le\u00f3n","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1242\/jcs.116285","article-title":"mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1.","volume":"126","author":"Denis","year":"2013","journal-title":"J. Cell Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.expneurol.2007.11.020","article-title":"Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats.","volume":"210","author":"Dhaenens","year":"2008","journal-title":"Exp. Neurol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.bbadis.2011.03.010","article-title":"Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing.","volume":"1812","author":"Dhaenens","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210813154019","article-title":"Mucoadhesive nanosystems for nose-to-brain drug delivery in the treatment of central nervous system diseases.","author":"Di Filippo","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.brainres.2006.01.083","article-title":"Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson\u2019s disease.","volume":"1082","author":"Dietz","year":"2006","journal-title":"Brain Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1469-8749.2012.04379.x","article-title":"Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1.","volume":"54","author":"Douniol","year":"2012","journal-title":"Dev. Med. Child Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nbd.2008.09.014","article-title":"Intergenerational and striatal CAG repeat instability in Huntington\u2019s disease knock-in mice involve different DNA repair genes.","volume":"33","author":"Dragileva","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1093\/hmg\/ddt386","article-title":"Length-dependent CTG\u22c5CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells.","volume":"22","author":"Du","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B79","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejpn.2007.07.014","article-title":"Myotonic dystrophy type I in childhood Long-term evolution in patients surviving the neonatal period.","volume":"12","author":"Echenne","year":"2008","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajmg.b.30698","article-title":"Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms.","author":"Ekstr\u00f6m","year":"2008","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1101\/gr.247239.118","article-title":"Decrypting noncoding RNA interactions, structures, and functional networks.","volume":"29","author":"Fabbri","year":"2019","journal-title":"Genome Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/hmg\/11.7.805","article-title":"Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.","volume":"11","author":"Fardaei","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"B83","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/hmg\/dds478","article-title":"Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients.","volume":"22","author":"Fernandez-Costa","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-981-32-9358-8_17","article-title":"Myotonic dystrophy: an RNA toxic gain of function tauopathy?","volume":"1184","author":"Fernandez-Gomez","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/wnl.42.1.91","article-title":"Decreased cerebral glucose utilization in myotonic dystrophy.","volume":"42","author":"Fiorelli","year":"1992","journal-title":"Neurology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/brain\/awz115","article-title":"MSH3 modifies somatic instability and disease severity in Huntington\u2019s and myotonic dystrophy type 1.","volume":"142","author":"Flower","year":"2019","journal-title":"Brain"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.4161\/cc.8.24.10245","article-title":"Over the barrier and through the blood: to CNS delivery we go.","volume":"8","author":"Foust","year":"2009","journal-title":"Cell Cycle"},{"key":"B88","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.nmd.2012.01.003","article-title":"Cerebral and muscle MRI abnormalities in myotonic dystrophy.","volume":"22","author":"Franc","year":"2012","journal-title":"Neuromusc. Disord."},{"key":"B89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nsmb.1958","article-title":"Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs.","volume":"18","author":"Francois","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10072-017-2811-2","article-title":"Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1.","volume":"38","author":"Fritegotto","year":"2017","journal-title":"Neurol. Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1126\/science.1546326","article-title":"An unstable triplet repeat in a gene related to myotonic muscular dystrophy.","volume":"255","author":"Fu","year":"1992","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.gt.3301955","article-title":"Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions.","volume":"10","author":"Furling","year":"2003","journal-title":"Gene Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/wnr.0000000000000968","article-title":"Macroscopic and microscopic diversity of missplicing in the central nervous system of patients with myotonic dystrophy type 1.","volume":"29","author":"Furuta","year":"2018","journal-title":"Neuroreport"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e3321","DOI":"10.1002\/jgm.3321","article-title":"U7 snRNA: a tool for gene therapy.","volume":"23","author":"Gadgil","year":"2021","journal-title":"J. Gene Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nmd.2016.10.003","article-title":"Cognitive decline over time in adults with myotonic dystrophy type 1: a 9-year longitudinal study.","volume":"27","author":"Gallais","year":"2017","journal-title":"Neuromusc. Disord."},{"key":"B96","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12883-015-0401-6","article-title":"Prevalence and correlates of apathy in myotonic dystrophy type 1.","volume":"15","author":"Gallais","year":"2015","journal-title":"BMC Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1479-5876-8-48","article-title":"Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients.","volume":"8","author":"Gambardella","year":"2010","journal-title":"J. Transl. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/mt.2016.97","article-title":"Genome therapy of myotonic dystrophy type 1 ips cells for development of autologous stem cell therapy.","volume":"24","author":"Gao","year":"2016","journal-title":"Mol. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"11866","DOI":"10.1073\/pnas.1018213108","article-title":"In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models.","volume":"108","author":"Garc\u00eda-L\u00f3pez","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B100","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.18632\/aging.103022","article-title":"Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin.","volume":"12","author":"Garc\u00eda-Puga","year":"2020","journal-title":"Aging"},{"key":"B101","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage.","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B103","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/ng.841","article-title":"The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain.","volume":"43","author":"Gehman","year":"2011","journal-title":"Nat. Genet."},{"key":"B104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/archneur.1988.00520250042017","article-title":"Central nervous system magnetic resonance imaging findings in myotonic dystrophy.","volume":"45","author":"Glantz","year":"1988","journal-title":"Arch. Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fncel.2019.00017","article-title":"The link between tau and insulin signaling: implications for Alzheimer\u2019s disease and other tauopathies.","volume":"13","author":"Gon\u00e7alves","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"662035","DOI":"10.3389\/fncel.2021.662035","article-title":"Integrative cell type-specific multi-omics approaches reveal impaired programs of glial cell differentiation in mouse culture models of DM1.","volume":"15","author":"Gonz\u00e1lez-Barriga","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.celrep.2015.07.029","article-title":"MBNL sequestration by toxic RNAs and RNA misprocessing in the myotonic dystrophy brain.","volume":"12","author":"Goodwin","year":"2015","journal-title":"Cell Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors.","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/hmg\/9.4.605","article-title":"Constitutive and regulated modes of splicing produce six major myotonic dystrophy protein kinase (DMPK) isoforms with distinct properties.","volume":"9","author":"Groenen","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1080\/15476286.2017.1279787","article-title":"Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.","volume":"14","author":"Gudde","year":"2017","journal-title":"RNA Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/hmg\/ddw042","article-title":"A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.","volume":"25","author":"Gudde","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B112","doi-asserted-by":"publisher","first-page":"15102","DOI":"10.1523\/jneurosci.3128-10.2010","article-title":"Regulation of dendritic spines, spatial memory, and embryonic development by the TANC family of PSD-95-interacting proteins.","volume":"30","author":"Han","year":"2010","journal-title":"J. Neurosci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/s0960-8966(02)00020-2","article-title":"99th ENMC international workshop: myotonic dystrophy: present management, future therapy. 9-11 November 2001, Naarden, The Netherlands.","volume":"12","author":"Harper","year":"2002","journal-title":"Neuromusc. Disord."},{"key":"B114","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/0387-7604(94)00097-h","article-title":"Neuroimaging study of myotonic dystrophy. II. MRI measurements of the brain.","volume":"17","author":"Hashimoto","year":"1995","journal-title":"Brain Dev."},{"key":"B115","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1212\/WNL.0b013e318260cbe6","article-title":"Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).","volume":"79","author":"Heatwole","year":"2012","journal-title":"Neurology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mus.24725","article-title":"Myotonic dystrophy health index: correlations with clinical tests and patient function.","volume":"53","author":"Heatwole","year":"2016","journal-title":"Muscle Nerve"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26066","article-title":"Myotonic dystrophy patient preferences in patient-reported outcome measures.","author":"Heatwole","year":"2018","journal-title":"Muscle Nerve"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1212\/wnl.0000000000011002","article-title":"Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial.","volume":"96","author":"Heatwole","year":"2021","journal-title":"Neurology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e0139944","DOI":"10.1371\/journal.pone.0139944","article-title":"Reconstructing the rasch-built myotonic dystrophy type 1 activity and participation scale.","volume":"10","author":"Hermans","year":"2015","journal-title":"PLoS One"},{"key":"B120","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/mus.23478","article-title":"Fatigue and daytime sleepiness scale in myotonic dystrophy type 1.","volume":"47","author":"Hermans","year":"2013","journal-title":"Muscle Nerve"},{"key":"B121","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/brain\/aws367","article-title":"Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour.","volume":"136","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"","journal-title":"Brain"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e25553","DOI":"10.4161\/rdis.25553","article-title":"Synaptic protein dysregulation in myotonic dystrophy type 1: disease neuropathogenesis beyond missplicing.","volume":"1","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"","journal-title":"Rare Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12035-017-0728-7","article-title":"Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson\u2019s disease.","volume":"55","author":"Hernando","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.nmd.2012.02.005","article-title":"Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1\u2013the patients\u2019 perspective.","volume":"22","author":"Hilton-Jones","year":"2012","journal-title":"Neuromusc. Disord."},{"key":"B125","doi-asserted-by":"publisher","first-page":"328","DOI":"10.15252\/emmm.201505846","article-title":"Therapeutic correction of ApoER2 splicing in Alzheimer\u2019s disease mice using antisense oligonucleotides.","volume":"8","author":"Hinrich","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/s0387-7604(84)80003-0","article-title":"Cerebrospinal fluid proteins in muscular dystrophy patients.","volume":"6","author":"Hirase","year":"1984","journal-title":"Brain Dev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2020.08.001","article-title":"A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1).","volume":"112","author":"Horrigan","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1093\/nar\/gku275","article-title":"Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.","volume":"42","author":"Hoskins","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/acs.biochem.7b01239","article-title":"Design of a \u201cmini\u201d nucleic acid probe for cooperative binding of an RNA-repeated transcript associated with myotonic dystrophy type 1.","volume":"57","author":"Hsieh","year":"2018","journal-title":"Biochemistry"},{"key":"B130","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.omtn.2020.11.014","article-title":"Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy.","volume":"23","author":"Hu","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B131","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e1003043","DOI":"10.1371\/journal.pgen.1003043","article-title":"Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus.","volume":"8","author":"Huguet","year":"2012","journal-title":"PLoS Genet."},{"key":"B133","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1267\/ahc.10019","article-title":"Neuropathology does not correlate with regional differences in the extent of expansion of CTG repeats in the brain with myotonic dystrophy type 1.","volume":"43","author":"Itoh","year":"2010","journal-title":"Acta Histochem. Cytochem."},{"key":"B134","doi-asserted-by":"publisher","first-page":"853.e6","DOI":"10.1016\/j.neuron.2018.01.020","article-title":"Rbfox splicing factors promote neuronal maturation and axon initial segment assembly.","volume":"97","author":"Jacko","year":"2018","journal-title":"Neuron"},{"key":"B135","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B136","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13023-014-0186-5","article-title":"Comparisons of intellectual capacities between mild and classic adult-onset phenotypes of myotonic dystrophy type 1 (DM1).","volume":"9","author":"Jean","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1021\/acschembio.8b00646","article-title":"Furamidine rescues myotonic dystrophy type I associated mis-splicing through multiple mechanisms.","volume":"13","author":"Jenquin","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1021\/acsptsci.9b00020","article-title":"Combination treatment of erythromycin and furamidine provides additive and synergistic rescue of mis-splicing in myotonic dystrophy type 1 models.","volume":"2","author":"Jenquin","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B139","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons.","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12725","article-title":"Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration.","author":"Jimenez-Marin","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mus.23717","article-title":"Somatic instability of CTG repeats in the cerebellum of myotonic dystrophy type 1.","volume":"48","author":"Jinnai","year":"2013","journal-title":"Muscle Nerve"},{"key":"B142","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1172\/jci64081","article-title":"GSK3\u03b2 mediates muscle pathology in myotonic dystrophy.","volume":"122","author":"Jones","year":"2012","journal-title":"J. Clin. Investig."},{"key":"B143","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.celrep.2013.12.025","article-title":"The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression.","volume":"6","author":"Kalsotra","year":"2014","journal-title":"Cell Rep."},{"key":"B144","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jconrel.2014.11.004","article-title":"Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.","volume":"197","author":"Kamei","year":"2015","journal-title":"J. Control. Release"},{"key":"B145","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.1073\/pnas.0604970103","article-title":"Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.","volume":"103","author":"Kanadia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/hmg\/ddt542","article-title":"High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines.","volume":"23","author":"Ketley","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B147","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jconrel.2020.01.016","article-title":"Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity.","volume":"319","author":"Khafagy","year":"2020","journal-title":"J. Control. Release"},{"key":"B148","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nbt.3784","article-title":"Oligonucleotide therapies for disorders of the nervous system.","volume":"35","author":"Khorkova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1161\/01.str.0000066869.45310.50","article-title":"Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice.","volume":"34","author":"Kilic","year":"2003","journal-title":"Stroke"},{"key":"B150","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000076669","article-title":"The TAT protein transduction domain enhances the neuroprotective effect of glial-cell-line-derived neurotrophic factor after optic nerve transection.","volume":"1","author":"Kilic","year":"2004","journal-title":"Neuro Degener. Dis."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/jcp.22609","article-title":"Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics.","volume":"226","author":"Kim","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1566523215666150630120537","article-title":"Therapeutic approaches for dominant muscle diseases: highlight on myotonic dystrophy.","volume":"15","author":"Klein","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"B153","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1172\/jci128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.","volume":"129","author":"Klein","year":"2019","journal-title":"J. Clin. Investig."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e107324","DOI":"10.1371\/journal.pone.0107324","article-title":"RBFOX1 cooperates with MBNL1 to control splicing in muscle, including events altered in myotonic dystrophy type 1.","volume":"9","author":"Klinck","year":"2014","journal-title":"PLoS One"},{"key":"B155","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"Cas guides the future of genetic engineering.","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"key":"B156","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.neures.2012.01.005","article-title":"Theory of mind impairment in adult-onset myotonic dystrophy type 1.","volume":"72","author":"Kobayakawa","year":"2012","journal-title":"Neurosci. Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jns.2009.11.011","article-title":"Facial emotion recognition and cerebral white matter lesions in myotonic dystrophy type 1.","volume":"290","author":"Kobayakawa","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/srep02242","article-title":"Ultrasound-enhanced delivery of morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice.","volume":"3","author":"Koebis","year":"2013","journal-title":"Sci. Rep."},{"key":"B159","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.3390\/jcm9123939","article-title":"The biomarker potential of miRNAs in myotonic dystrophy type I.","volume":"9","author":"Koehorst","year":"2020","journal-title":"J. Clin. Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B161","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1464-5491.2005.01432.x","article-title":"Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.","volume":"22","author":"Kouki","year":"2005","journal-title":"Diabetic Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1242\/jcs.172288","article-title":"MyoD transcription factor induces myogenesis by inhibiting Twist-1 through miR-206.","volume":"128","author":"Koutalianos","year":"2015","journal-title":"J. Cell Sci."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e0125341","DOI":"10.1371\/journal.pone.0125341","article-title":"Elevated muscle-specific miRNAs in serum of myotonic dystrophy patients relate to muscle disease progress.","volume":"10","author":"Koutsoulidou","year":"2015","journal-title":"PLoS One"},{"key":"B164","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1093\/hmg\/ddx212","article-title":"Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress.","volume":"26","author":"Koutsoulidou","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B165","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos.","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B166","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00415-014-7566-6","article-title":"Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography.","volume":"262","author":"Krogias","year":"2015","journal-title":"J. Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/jon.12328","article-title":"Transcranial sonography findings in depression in association with psychiatric and neurologic diseases: a review.","volume":"26","author":"Krogias","year":"2016","journal-title":"J. Neuroimaging"},{"key":"B168","doi-asserted-by":"publisher","first-page":"142","DOI":"10.14712\/18059694.2015.79","article-title":"Nanotechnology - new trends in the treatment of brain tumours.","volume":"57","author":"Krupa","year":"2014","journal-title":"Acta Med."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1152\/physrev.00032.2015","article-title":"Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans.","volume":"96","author":"Kullmann","year":"2016","journal-title":"Physiol. Rev."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/s0196-9781(00)00339-9","article-title":"Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.","volume":"21","author":"Kumar","year":"2000","journal-title":"Peptides"},{"key":"B171","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.","volume":"28","author":"Kuyumcu-Martinez","year":"2007","journal-title":"Mol. Cell"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e0204227","DOI":"10.1371\/journal.pone.0204227","article-title":"Social cognition in myotonic dystrophy type 1: specific or secondary impairment?","volume":"13","author":"Labayru","year":"2018","journal-title":"PLoS One"},{"key":"B173","doi-asserted-by":"publisher","first-page":"102078","DOI":"10.1016\/j.nicl.2019.102078","article-title":"Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1.","volume":"24","author":"Labayru","year":"2019","journal-title":"Neuroimage Clin."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/acn3.51163","article-title":"Neurodegeneration trajectory in pediatric and adult\/late DM1: a follow-up MRI study across a decade.","volume":"7","author":"Labayru","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11910-013-0340-9","article-title":"Daytime sleepiness and myotonic dystrophy.","volume":"13","author":"Laberge","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B176","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.mcn.2012.12.003","article-title":"CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.","volume":"56","author":"Ladd","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1128\/mcb.21.4.1285-1296.2001","article-title":"The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing.","volume":"21","author":"Ladd","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"17756","DOI":"10.1074\/jbc.M310687200","article-title":"CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing.","volume":"279","author":"Ladd","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B179","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jnr.24595","article-title":"Cognitive function and its relationship with brain structure in myotonic dystrophy type 1.","volume":"99","author":"Langbehn","year":"2021","journal-title":"J. Neurosci. Res."},{"key":"B180","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/1756-0500-4-490","article-title":"Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules.","volume":"4","author":"Larsen","year":"2011","journal-title":"BMC Res. Notes"},{"key":"B181","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1038\/mtna.2015.35","article-title":"In vitro and In vivo modulation of alternative splicing by the biguanide metformin.","volume":"4","author":"Laustriat","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/mt.2013.121","article-title":"AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.","volume":"21","author":"Le Hir","year":"2013","journal-title":"Mol. Ther."},{"key":"B183","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.addr.2007.09.002","article-title":"Cell penetrating peptide conjugates of steric block oligonucleotides.","volume":"60","author":"Lebleu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B184","doi-asserted-by":"publisher","first-page":"102562","DOI":"10.1016\/j.nicl.2021.102562","article-title":"Lesion distribution and substrate of white matter damage in myotonic dystrophy type 1: comparison with multiple sclerosis.","volume":"29","author":"Leddy","year":"2021","journal-title":"Neuroimage Clin."},{"key":"B185","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fgene.2016.00047","article-title":"Genome engineering with TALE and CRISPR systems in neuroscience.","volume":"7","author":"Lee","year":"2016","journal-title":"Front. Genet."},{"key":"B186","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1117019109","article-title":"RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B187","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair.","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"B188","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnana.2019.00075","article-title":"Deprivation of muscleblind-like proteins causes deficits in cortical neuron distribution and morphological changes in dendritic spines and postsynaptic densities.","volume":"13","author":"Lee","year":"2019","journal-title":"Front. Neuroanat."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/emmm.201303275","article-title":"Compound loss of muscleblind-like function in myotonic dystrophy.","volume":"5","author":"Lee","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/17425247.2012.689285","article-title":"Cell-penetrating peptides for the delivery of nucleic acids.","volume":"9","author":"Lehto","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"B191","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/jnr.20980","article-title":"ETR-3 represses Tau exons 2\/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I.","volume":"84","author":"Leroy","year":"","journal-title":"J. Neurosci. Res."},{"key":"B192","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bbadis.2005.12.003","article-title":"Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1.","volume":"1762","author":"Leroy","year":"","journal-title":"Biochim. Biophys. Acta"},{"key":"B193","doi-asserted-by":"publisher","first-page":"e00279","DOI":"10.1128\/aac.00279-17","article-title":"A phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza B virus monoclonal antibody, MHAB5553A, in healthy volunteers.","volume":"61","author":"Lim","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/dmcn.14161","article-title":"Cognitive and adaptive functioning in congenital and childhood forms of myotonic dystrophy type 1: a longitudinal study.","volume":"61","author":"Lindeblad","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.ymthe.2019.05.021","article-title":"Genome editing of expanded CTG repeats within the human DMPK gene reduces nuclear RNA foci in the muscle of DM1 mice.","volume":"27","author":"Lo Scrudato","year":"2019","journal-title":"Mol. Ther."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamaneurol.2016.3388","article-title":"Genome editing of monogenic neuromuscular diseases: a systematic review.","volume":"73","author":"Long","year":"2016","journal-title":"JAMA Neurol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.3390\/ijms20225600","article-title":"MicroRNA-based therapeutic perspectives in myotonic dystrophy.","volume":"20","author":"L\u00f3pez Castel","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B199","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fneur.2018.00349","article-title":"Small molecules which improve pathogenesis of myotonic dystrophy type 1.","volume":"9","author":"L\u00f3pez-Morat\u00f3","year":"2018","journal-title":"Front. Neurol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jon.12786","article-title":"Cognitive decline and white matter integrity degradation in myotonic dystrophy type I.","volume":"31","author":"Lopez-Titla","year":"2021","journal-title":"J. Neuroimaging"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/cmdc.201600081","article-title":"A potent inhibitor of protein sequestration by expanded triplet (CUG) repeats that shows phenotypic improvements in a drosophila model of myotonic dystrophy.","volume":"11","author":"Luu","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"B202","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jnr.22551","article-title":"Perspectives on gene therapy in myotonic dystrophy type 1.","volume":"89","author":"Maga\u00f1a","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","article-title":"Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2032 untranslated region of the gene.","volume":"255","author":"Mahadevan","year":"1992","journal-title":"Science"},{"key":"B204","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1021\/acschembio.7b00416","article-title":"BNA (NC) gapmers revert splicing and reduce RNA foci with low toxicity in myotonic dystrophy cells.","volume":"12","author":"Manning","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.stem.2011.02.004","article-title":"Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy.","volume":"8","author":"Marteyn","year":"2011","journal-title":"Cell Stem Cell"},{"key":"B206","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/sleep\/26.3.287","article-title":"Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness.","volume":"26","author":"Mart\u00ednez-Rodr\u00edguez","year":"2003","journal-title":"Sleep"},{"key":"B207","doi-asserted-by":"publisher","first-page":"e9857","DOI":"10.1371\/journal.pone.0009857","article-title":"Muscleblind1, but not Dmpk or Six5, contributes to a complex phenotype of muscular and motivational deficits in mouse models of myotonic dystrophy.","volume":"5","author":"Matynia","year":"2010","journal-title":"PLoS One"},{"key":"B208","doi-asserted-by":"publisher","first-page":"109","DOI":"10.36185\/2532-1900-015","article-title":"Predictors of prognosis in type 1 myotonic dystrophy (DM1): longitudinal 18-years experience from a single center.","volume":"39","author":"Mazzoli","year":"2020","journal-title":"Acta Myol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4155\/tde.15.30","article-title":"Challenges and new strategies for therapeutic peptide delivery to the CNS.","volume":"6","author":"McGowan","year":"2015","journal-title":"Ther. Deliv."},{"key":"B210","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.2147\/dddt.s106216","article-title":"Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system.","volume":"10","author":"McGowan","year":"2016","journal-title":"Drug Design Dev. Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.nlm.2009.06.012","article-title":"Impaired long-term potentiation and enhanced neuronal excitability in the amygdala of Ca(V)1.3 knockout mice.","volume":"92","author":"McKinney","year":"2009","journal-title":"Neurobiol. Learn. Mem."},{"key":"B212","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbadis.2014.05.019","article-title":"Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms.","volume":"1852","author":"Meola","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B213","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/mus.20800","article-title":"Cerebral involvement in myotonic dystrophies.","volume":"36","author":"Meola","year":"2007","journal-title":"Muscle Nerve"},{"key":"B214","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0960-8966(03)00137-8","article-title":"Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM\/DM-2).","volume":"13","author":"Meola","year":"2003","journal-title":"Neuromusc. Disord."},{"key":"B215","doi-asserted-by":"publisher","first-page":"700796","DOI":"10.3389\/fneur.2021.700796","article-title":"Cognitive deficits, apathy, and hypersomnolence represent the core brain symptoms of adult-onset myotonic dystrophy type 1.","volume":"12","author":"Miller","year":"2021","journal-title":"Front. Neurol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","article-title":"Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.","volume":"19","author":"Miller","year":"2000","journal-title":"Embo J."},{"key":"B217","doi-asserted-by":"publisher","first-page":"Cd001447","DOI":"10.1002\/14651858.CD001447.pub3","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND).","volume":"2012","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B218","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3233\/jnd-180310","article-title":"A review of psychopathology features, personality, and coping in myotonic dystrophy type 1.","volume":"5","author":"Minier","year":"2018","journal-title":"J. Neuromusc. Dis."},{"key":"B220","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fneur.2018.00646","article-title":"Current progress in CNS imaging of myotonic dystrophy.","volume":"9","author":"Minnerop","year":"2018","journal-title":"Front. Neurol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1093\/brain\/awr299","article-title":"The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease.","volume":"134","author":"Minnerop","year":"2011","journal-title":"Brain"},{"key":"B222","doi-asserted-by":"publisher","first-page":"748.e6","DOI":"10.1016\/j.devcel.2020.01.037","article-title":"Aberrant expression of a non-muscle RBFOX2 isoform triggers cardiac conduction defects in myotonic dystrophy.","volume":"52","author":"Misra","year":"2020","journal-title":"Dev. Cell"},{"key":"B223","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1440-1819.1999.00470.x","article-title":"An autopsy case of myotonic dystrophy with mental disorders and various neuropathologic features.","volume":"53","author":"Mizukami","year":"1999","journal-title":"Psychiatry Clin. Neurosci."},{"key":"B224","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bpa.12603","article-title":"Four-repeat tau dominant pathology in a congenital myotonic dystrophy type 1 patient with mental retardation.","volume":"28","author":"Mizuno","year":"2018","journal-title":"Brain Pathol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00415-008-0017-5","article-title":"Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study.","volume":"255","author":"Modoni","year":"2008","journal-title":"J. Neurol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.brainres.2014.03.039","article-title":"RNA-protein interactions in unstable microsatellite diseases.","volume":"1584","author":"Mohan","year":"2014","journal-title":"Brain Res."},{"key":"B227","doi-asserted-by":"publisher","first-page":"dmm034728","DOI":"10.1242\/dmm.034728","article-title":"Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery.","volume":"11","author":"Mondragon-Gonzalez","year":"2018","journal-title":"Dis. Models Mech."},{"key":"B228","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/hmg\/ddaa123","article-title":"Longitudinal increases in somatic mosaicism of the expanded CTG repeat in myotonic dystrophy type 1 are associated with variation in age-at-onset.","volume":"29","author":"Morales","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"B230","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1172\/jci109198","article-title":"Decreased insulin sensitivity of forearm muscle in myotonic dystrophy.","volume":"62","author":"Moxley","year":"1978","journal-title":"J. Clin. Investig."},{"key":"B231","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.0905780106","article-title":"Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.","volume":"106","author":"Mulders","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B232","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1093\/hmg\/ddq161","article-title":"Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.","volume":"19","author":"Mulders","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B233","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrd3459","article-title":"Targeting RNA to treat neuromuscular disease.","volume":"10","author":"Muntoni","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B234","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1038\/mtna.2016.49","article-title":"CNS-restricted transduction and CRISPR\/Cas9-mediated gene deletion with an engineered AAV vector.","volume":"5","author":"Murlidharan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B235","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/mt.2011.191","article-title":"Stabilization of expanded (CTG)\u2022(CAG) repeats by antisense oligonucleotides.","volume":"19","author":"Nakamori","year":"2011","journal-title":"Mol. Ther."},{"key":"B236","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/WNR.0b013e328358720b","article-title":"Cyclin-dependent kinase 5 immunoreactivity for granulovacuolar degeneration.","volume":"23","author":"Nakamori","year":"2012","journal-title":"Neuroreport"},{"key":"B237","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/acn3.271","article-title":"Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy.","volume":"3","author":"Nakamori","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"14305","DOI":"10.1002\/chem.202001572","article-title":"The dimeric form of 1,3-diaminoisoquinoline derivative rescued the mis-splicing of Atp2a1 and Clcn1 genes in myotonic dystrophy type 1 mouse model.","volume":"26","author":"Nakatani","year":"2020","journal-title":"Chemistry"},{"key":"B239","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jconrel.2021.08.027","article-title":"Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner.","volume":"338","author":"Nehra","year":"2021","journal-title":"J. Control. Release"},{"key":"B240","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2017.126","article-title":"Genome engineering: a new approach to gene therapy for neuromuscular disorders.","volume":"13","author":"Nelson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-0716-0771-8_7","article-title":"Degradation of toxic RNA in myotonic dystrophy using gapmer antisense oligonucleotides.","volume":"2176","author":"Nguyen","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3389\/fneur.2019.01229","article-title":"Insulin signaling as a key moderator in myotonic dystrophy type 1.","volume":"10","author":"Nieuwenhuis","year":"2019","journal-title":"Front. Neurol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"e0224912","DOI":"10.1371\/journal.pone.0224912","article-title":"Differences in splicing defects between the grey and white matter in myotonic dystrophy type 1 patients.","volume":"15","author":"Nishi","year":"2020","journal-title":"PLoS One"},{"key":"B244","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1101\/gad.328963.119","article-title":"Cell-type-specific dysregulation of RNA alternative splicing in short tandem repeat mouse knockin models of myotonic dystrophy.","volume":"33","author":"Nutter","year":"2019","journal-title":"Genes Dev."},{"key":"B245","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/srep02142","article-title":"Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice.","volume":"3","author":"Oana","year":"2013","journal-title":"Sci. Rep."},{"key":"B246","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1093\/nar\/gks298","article-title":"From dynamic combinatorial \u2018hit\u2019 to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy.","volume":"40","author":"Ofori","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B247","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s002340050613","article-title":"Anterior temporal white matter lesions in myotonic dystrophy with intellectual impairment: an MRI and neuropathological study.","volume":"40","author":"Ogata","year":"1998","journal-title":"Neuroradiology"},{"key":"B248","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cortex.2017.08.008","article-title":"The cognitive profile of myotonic dystrophy type 1: a systematic review and meta-analysis.","volume":"95","author":"Okkersen","year":"","journal-title":"Cortex"},{"key":"B249","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1212\/wnl.0000000000004300","article-title":"Brain imaging in myotonic dystrophy type 1: a systematic review.","volume":"89","author":"Okkersen","year":"","journal-title":"Neurology"},{"key":"B250","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s1474-4422(18)30203-5","article-title":"Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.","volume":"17","author":"Okkersen","year":"2018","journal-title":"Lancet Neurol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/bf00296355","article-title":"Neuronal cell loss in the dorsal raphe nucleus and the superior central nucleus in myotonic dystrophy: a clinicopathological correlation.","volume":"89","author":"Ono","year":"1995","journal-title":"Acta Neuropathol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/wnl.46.1.228","article-title":"Neuronal loss in the medullary reticular formation in myotonic dystrophy: a clinicopathological study.","volume":"46","author":"Ono","year":"1996","journal-title":"Neurology"},{"key":"B253","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1212\/wnl.50.2.535","article-title":"Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia.","volume":"50","author":"Ono","year":"1998","journal-title":"Neurology"},{"key":"B254","doi-asserted-by":"publisher","first-page":"108634","DOI":"10.1016\/j.celrep.2020.108634","article-title":"Transcriptome alterations in myotonic dystrophy frontal cortex.","volume":"34","author":"Otero","year":"2021","journal-title":"Cell Rep."},{"key":"B255","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/mus.21352","article-title":"DMPK protein isoforms are differentially expressed in myogenic and neural cell lineages.","volume":"40","author":"Oude Ophuis","year":"2009","journal-title":"Muscle Nerve"},{"key":"B256","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/jpet.115.226969","article-title":"Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.","volume":"355","author":"Pandey","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B257","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.drudis.2021.03.024","article-title":"Myotonic dystrophy type 1 drug development: a pipeline toward the market.","volume":"26","author":"Pascual-Gilabert","year":"2021","journal-title":"Drug Discov. Today"},{"key":"B258","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s10072-020-04409-2","article-title":"MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy.","volume":"41","author":"Pegoraro","year":"2020","journal-title":"Neurol. Sci."},{"key":"B259","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nmd.2010.11.012","article-title":"Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1.","volume":"21","author":"Perbellini","year":"2011","journal-title":"Neuromusc. Disord."},{"key":"B260","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.nmd.2014.02.005","article-title":"Plasma microRNAs as biomarkers for myotonic dystrophy type 1.","volume":"24","author":"Perfetti","year":"2014","journal-title":"Neuromusc. Disord."},{"key":"B261","doi-asserted-by":"publisher","first-page":"38174","DOI":"10.1038\/srep38174","article-title":"Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1.","volume":"6","author":"Perfetti","year":"2016","journal-title":"Sci. Rep."},{"key":"B262","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jns.2017.05.013","article-title":"Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2.","volume":"378","author":"Peric","year":"","journal-title":"J. Neurol. Sci."},{"key":"B263","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/ane.12788","article-title":"Prospective measurement of quality of life in myotonic dystrophy type 1.","volume":"136","author":"Peric","year":"","journal-title":"Acta Neurol. Scand."},{"key":"B264","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mus.24162","article-title":"Transcranial sonography in patients with myotonic dystrophy type 1.","volume":"50","author":"Peric","year":"","journal-title":"Muscle Nerve"},{"key":"B265","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ene.12237","article-title":"Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1.","volume":"21","author":"Peric","year":"","journal-title":"Eur. J. Neurol."},{"key":"B266","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ane.12549","article-title":"Five-year study of quality of life in myotonic dystrophy.","volume":"134","author":"Peric","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"B267","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/nar\/gkv029","article-title":"Molecular mechanisms in DM1 - a focus on foci.","volume":"43","author":"Pettersson","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B268","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.nmd.2011.08.010","article-title":"Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1.","volume":"22","author":"Pincherle","year":"2012","journal-title":"Neuromusc. Disord."},{"key":"B269","doi-asserted-by":"publisher","first-page":"479.e5","DOI":"10.1016\/j.molcel.2017.09.033","article-title":"Impeding transcription of expanded microsatellite repeats by deactivated Cas9.","volume":"68","author":"Pinto","year":"2017","journal-title":"Mol. Cell"},{"key":"B270","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.nmd.2006.06.007","article-title":"Sleep disorders in childhood-onset myotonic dystrophy type 1.","volume":"16","author":"Quera Salva","year":"2006","journal-title":"Neuromusc. Disord."},{"key":"B271","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/ijms20153689","article-title":"CRISPR\/Cas applications in myotonic dystrophy: expanding opportunities.","volume":"20","author":"Raaijmakers","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B272","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clineuro.2014.08.021","article-title":"Significant impact of behavioral and cognitive impairment on quality of life in patients with myotonic dystrophy type 1.","volume":"126","author":"Rakocevic-Stojanovic","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B273","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/cercor\/bhy164","article-title":"Methylphenidate attenuates the cognitive and mood alterations observed in Mbnl2 knockout mice and reduces microglia overexpression.","volume":"29","author":"Ramon-Duaso","year":"2019","journal-title":"Cerebr. Cortex"},{"key":"B274","doi-asserted-by":"publisher","first-page":"108030","DOI":"10.1016\/j.neuropharm.2020.108030","article-title":"Protective effects of mirtazapine in mice lacking the Mbnl2 gene in forebrain glutamatergic neurons: relevance for myotonic dystrophy 1.","volume":"170","author":"Ramon-Duaso","year":"2020","journal-title":"Neuropharmacology"},{"key":"B275","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nsmb.2067","article-title":"Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy.","volume":"18","author":"Rau","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B276","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/ijms20164017","article-title":"Mitigating RNA toxicity in myotonic dystrophy using small molecules.","volume":"20","author":"Reddy","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B277","doi-asserted-by":"publisher","first-page":"20991","DOI":"10.1073\/pnas.1901893116","article-title":"A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.","volume":"116","author":"Reddy","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B278","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ng0796-325","article-title":"Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy.","volume":"13","author":"Reddy","year":"1996","journal-title":"Nat. Genet."},{"key":"B279","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12883-016-0630-3","article-title":"In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8.","volume":"16","author":"Renard","year":"2016","journal-title":"BMC Neurol."},{"key":"B280","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tig.2015.02.003","article-title":"Shortening trinucleotide repeats using highly specific endonucleases: a possible approach to gene therapy?","volume":"31","author":"Richard","year":"2015","journal-title":"Trends Genet."},{"key":"B281","doi-asserted-by":"publisher","first-page":"e95611","DOI":"10.1371\/journal.pone.0095611","article-title":"Highly specific contractions of a single CAG\/CTG trinucleotide repeat by TALEN in yeast.","volume":"9","author":"Richard","year":"2014","journal-title":"PLoS One"},{"key":"B282","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10072-010-0406-2","article-title":"Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients.","volume":"31","author":"Romeo","year":"","journal-title":"Neurol. Sci."},{"key":"B283","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00415-010-5498-3","article-title":"Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2.","volume":"257","author":"Romeo","year":"","journal-title":"J. Neurol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/0092-8674(93)90487-b","article-title":"Short-term synaptic plasticity is altered in mice lacking synapsin I.","volume":"75","author":"Rosahl","year":"1993","journal-title":"Cell"},{"key":"B285","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/brain\/89.4.769","article-title":"Mental deficiency associated with muscular dystrophy. A neuropathological study.","volume":"89","author":"Rosman","year":"1966","journal-title":"Brain"},{"key":"B286","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.omtn.2019.11.012","article-title":"miR-7 restores phenotypes in myotonic dystrophy muscle cells by repressing hyperactivated autophagy.","volume":"19","author":"Sabater-Arcis","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B287","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrn3837","article-title":"The role of orexin in motivated behaviours.","volume":"15","author":"Sakurai","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"B288","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10072-009-0048-4","article-title":"Comparative transcriptional and biochemical studies in muscle of myotonic dystrophies (DM1 and DM2).","volume":"30","author":"Salvatori","year":"2009","journal-title":"Neurol. Sci."},{"key":"B289","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10072-007-0742-z","article-title":"Cognitive impairment in adult myotonic dystrophies: a longitudinal study.","volume":"28","author":"Sansone","year":"2007","journal-title":"Neurol. Sci."},{"key":"B290","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s12035-015-9219-x","article-title":"Chronic treatment with a clinically relevant dose of methylphenidate increases glutamate levels in cerebrospinal fluid and impairs glutamatergic homeostasis in prefrontal cortex of juvenile rats.","volume":"53","author":"Schmitz","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"B291","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.1007\/s12035-016-0289-1","article-title":"Methylphenidate decreases ATP levels and impairs glutamate uptake and Na(+),K(+)-ATPase activity in juvenile rat hippocampus.","volume":"54","author":"Schmitz","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"e0130352","DOI":"10.1371\/journal.pone.0130352","article-title":"Cortical and subcortical grey and white matter atrophy in myotonic dystrophies type 1 and 2 is associated with cognitive impairment, depression and daytime sleepiness.","volume":"10","author":"Schneider-Gold","year":"2015","journal-title":"PLoS One"},{"key":"B293","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases.","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"B294","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000511962","article-title":"New insights in adherence and survival in myotonic dystrophy patients using home mechanical ventilation.","volume":"100","author":"Seijger","year":"2021","journal-title":"Respir. Int. Rev. Thor. Dis."},{"key":"B295","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41467-018-04370-x","article-title":"rbFOX1\/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1\/type 2 differences.","volume":"9","author":"Sellier","year":"2018","journal-title":"Nat. Commun."},{"key":"B296","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/hmg\/10.19.2143","article-title":"Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.","volume":"10","author":"Sergeant","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"B297","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cortex.2020.03.022","article-title":"Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1.","volume":"128","author":"Serra","year":"","journal-title":"Cortex"},{"key":"B298","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fneur.2020.00113","article-title":"Abnormal cortical thickness is associated with deficits in social cognition in patients with myotonic dystrophy type 1.","volume":"11","author":"Serra","year":"","journal-title":"Front. Neurol."},{"key":"B299","doi-asserted-by":"publisher","first-page":"e0156901","DOI":"10.1371\/journal.pone.0156901","article-title":"\u201cI know that you know that i know\u201d: neural substrates associated with social cognition deficits in DM1 patients.","volume":"11","author":"Serra","year":"","journal-title":"PLoS One"},{"key":"B300","doi-asserted-by":"publisher","first-page":"2696085","DOI":"10.1155\/2016\/2696085","article-title":"Brain connectomics\u2019 modification to clarify motor and nonmotor features of myotonic dystrophy type 1.","volume":"2016","author":"Serra","year":"","journal-title":"Neural Plast."},{"key":"B301","first-page":"21","article-title":"How genetics affects the brain to produce higher-level dysfunctions in myotonic dystrophy type 1.","volume":"30","author":"Serra","year":"2015","journal-title":"Funct. Neurol."},{"key":"B302","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamaneurol.2014.130","article-title":"Abnormal functional brain connectivity and personality traits in myotonic dystrophy type 1.","volume":"71","author":"Serra","year":"2014","journal-title":"JAMA Neurol."},{"key":"B303","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1126\/science.290.5494.1170","article-title":"NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation.","volume":"290","author":"Shimizu","year":"2000","journal-title":"Science"},{"key":"B304","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.celrep.2015.11.028","article-title":"Actinomycin D specifically reduces expanded CUG repeat RNA in myotonic dystrophy models.","volume":"13","author":"Siboni","year":"","journal-title":"Cell Rep."},{"key":"B305","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1021\/acs.jmedchem.5b00356","article-title":"Biological efficacy and toxicity of diamidines in myotonic dystrophy type 1 models.","volume":"58","author":"Siboni","year":"","journal-title":"J. Med. Chem."},{"key":"B306","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/j.celrep.2017.06.006","article-title":"Downregulation of the glial GLT1 glutamate transporter and purkinje cell dysfunction in a mouse model of myotonic dystrophy.","volume":"19","author":"Sicot","year":"2017","journal-title":"Cell Rep."},{"key":"B307","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fneur.2020.00624","article-title":"Central nervous system involvement as outcome measure for clinical trials efficacy in myotonic dystrophy type 1.","volume":"11","author":"Simoncini","year":"2020","journal-title":"Front. Neurol."},{"key":"B308","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molcel.2014.06.035","article-title":"Rbfox2-coordinated alternative splicing of Mef2d and Rock2 controls myoblast fusion during myogenesis.","volume":"55","author":"Singh","year":"2014","journal-title":"Mol. Cell"},{"key":"B309","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1017\/s0033291709990602","article-title":"Cognitive\/personality pattern and triplet expansion size in adult myotonic dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1.","volume":"40","author":"Sistiaga","year":"2010","journal-title":"Psychol. Med."},{"key":"B310","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/jci25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease.","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Investig."},{"key":"B311","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/mt.2012.222","article-title":"RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.","volume":"21","author":"Sobczak","year":"2013","journal-title":"Mol. Ther."},{"key":"B312","doi-asserted-by":"publisher","first-page":"111510","DOI":"10.1016\/j.mad.2021.111510","article-title":"New insights into molecular changes in skeletal muscle aging and disease: differential alternative splicing and senescence.","volume":"197","author":"Solovyeva","year":"2021","journal-title":"Mech. Age. Dev."},{"key":"B313","doi-asserted-by":"publisher","first-page":"10118","DOI":"10.3390\/ijms221810118","article-title":"Design and development of nanomaterial-based drug carriers to overcome the blood-brain barrier by using different transport mechanisms.","volume":"22","author":"Song","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B314","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41419-020-02756-8","article-title":"MBNL1 reverses the proliferation defect of skeletal muscle satellite cells in myotonic dystrophy type 1 by inhibiting autophagy via the mTOR pathway.","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"B315","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1093\/nar\/gkaa007","article-title":"AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for myotonic dystrophy type 1.","volume":"48","author":"Stepniak-Konieczna","year":"2020","journal-title":"Nucleic Acids Research"},{"key":"B316","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1399-0004.1997.tb02533.x","article-title":"A study of the cognitive and psychological profile in 16 children with congenital or juvenile myotonic dystrophy.","volume":"52","author":"Steyaert","year":"1997","journal-title":"Clin. Genet."},{"key":"B317","doi-asserted-by":"publisher","first-page":"e32724","DOI":"10.7554\/eLife.32724","article-title":"RNA-dependent RNA targeting by CRISPR-Cas9.","volume":"7","author":"Strutt","year":"2018","journal-title":"eLife"},{"key":"B318","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/mus.26866","article-title":"Sleep disorders in myotonic dystrophies.","volume":"62","author":"Subramony","year":"2020","journal-title":"Muscle Nerve"},{"key":"B319","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev.neuro.26.041002.131412","article-title":"The synaptic vesicle cycle.","volume":"27","author":"Sudhof","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"B320","doi-asserted-by":"publisher","first-page":"e33218","DOI":"10.1371\/journal.pone.0033218","article-title":"Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.","volume":"7","author":"Suenaga","year":"2012","journal-title":"PLoS One"},{"key":"B321","doi-asserted-by":"publisher","first-page":"e0187343","DOI":"10.1371\/journal.pone.0187343","article-title":"Brain gray matter structural network in myotonic dystrophy type 1.","volume":"12","author":"Sugiyama","year":"2017","journal-title":"PLoS One"},{"key":"B322","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s0167-4781(99)00150-5","article-title":"Morpholino antisense oligomers: the case for an RNase H-independent structural type.","volume":"1489","author":"Summerton","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"B323","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/bit.24890","article-title":"Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing.","volume":"110","author":"Sun","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"B324","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1177\/0961203318778767","article-title":"Cerebrospinal fluid orexin-A levels in systemic lupus erythematosus patients presenting with excessive daytime sleepiness.","volume":"27","author":"Suzuki","year":"2018","journal-title":"Lupus"},{"key":"B325","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1128\/mcb.00619-10","article-title":"An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1.","volume":"30","author":"Suzuki","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"B326","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/mus.25469","article-title":"Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients.","volume":"56","author":"Symonds","year":"2017","journal-title":"Muscle Nerve"},{"key":"B327","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000371575","article-title":"Diffuse brain abnormalities in myotonic dystrophy type 1 detected by 3.0 T proton magnetic resonance spectroscopy.","volume":"73","author":"Takado","year":"2015","journal-title":"Eur. Neurol."},{"key":"B328","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2009.01.014","article-title":"Lowered sensitivity to facial emotions in myotonic dystrophy type 1.","volume":"280","author":"Takeda","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"B329","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1093\/nar\/24.22.4407","article-title":"Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy.","volume":"24","author":"Timchenko","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"B330","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1242\/dmm.012427","article-title":"Transcriptional changes and developmental abnormalities in a zebrafish model of myotonic dystrophy type 1.","volume":"7","author":"Todd","year":"2014","journal-title":"Dis. Models Mech."},{"key":"B331","doi-asserted-by":"publisher","first-page":"e1000482","DOI":"10.1371\/journal.pgen.1000482","article-title":"MSH2 ATPase domain mutation affects CTG\u2217CAG repeat instability in transgenic mice.","volume":"5","author":"Tom\u00e9","year":"2009","journal-title":"PLoS Genet."},{"key":"B332","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ane.12360","article-title":"Cortical involvement during myotonia in myotonic dystrophy: an fMRI study.","volume":"132","author":"Toth","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"B333","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40359-021-00562-1","article-title":"Accomplishment of instrumental activities of daily living and its relationship with cognitive functions in adults with myotonic dystrophy type 1 childhood phenotype: an exploratory study.","volume":"9","author":"Tremblay","year":"2021","journal-title":"BMC Psychol."},{"key":"B334","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/s1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges.","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol."},{"key":"B335","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","article-title":"CRISPR\/Cas9-induced (CTG\u22c5CAG)(n) repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing.","volume":"25","author":"van Agtmaal","year":"2017","journal-title":"Mol. Ther."},{"key":"B336","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41398-019-0559-6","article-title":"Converging evidence points towards a role of insulin signaling in regulating compulsive behavior.","volume":"9","author":"van de Vondervoort","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"B337","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1503\/jpn.140327","article-title":"An integrated molecular landscape implicates the regulation of dendritic spine formation through insulin-related signalling in obsessive-compulsive disorder.","volume":"41","author":"van de Vondervoort","year":"2016","journal-title":"J. Psychiatry Neurosci."},{"key":"B338","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1038\/s41598-018-22316-7","article-title":"Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis.","volume":"8","author":"van der Bent","year":"2018","journal-title":"Sci. Rep."},{"key":"B339","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/jnd-190397","article-title":"Brain structural features of myotonic dystrophy type 1 and their relationship with CTG repeats.","volume":"6","author":"van der Plas","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"B340","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jad.2019.03.036","article-title":"Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis.","volume":"250","author":"van der Velden","year":"2019","journal-title":"J. Affect. Disord."},{"key":"B341","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13063-015-0737-7","article-title":"Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial.","volume":"16","author":"van Engelen","year":"2015","journal-title":"Trials"},{"key":"B342","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10072-019-03764-z","article-title":"Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.","volume":"40","author":"Vita","year":"2019","journal-title":"Neurol. Sci."},{"key":"B343","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3390\/ijms20081938","article-title":"Dysregulation of circular RNAs in myotonic dystrophy type 1.","volume":"20","author":"Voellenkle","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B344","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1073\/pnas.85.14.5011","article-title":"Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.","volume":"85","author":"Walder","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B345","first-page":"161","article-title":"Psychometric and cranial CT study in myotonic dystrophy.","volume":"20","author":"Walker","year":"1984","journal-title":"Clin. Exp. Neurol."},{"key":"B346","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.cell.2012.06.041","article-title":"Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins.","volume":"150","author":"Wang","year":"2012","journal-title":"Cell"},{"key":"B347","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1523\/jneurosci.2352-16.2016","article-title":"Dysregulation of mRNA localization and translation in genetic disease.","volume":"36","author":"Wang","year":"2016","journal-title":"J. Neurosci."},{"key":"B348","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1172\/jci37976","article-title":"PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.","volume":"119","author":"Wang","year":"2009","journal-title":"J. Clin. Investig."},{"key":"B349","doi-asserted-by":"publisher","first-page":"e00155","DOI":"10.1128\/mcb.00155-19","article-title":"Correction of glycogen synthase kinase 3\u03b2 in myotonic dystrophy 1 reduces the mutant RNA and improves postnatal survival of DMSXL mice.","volume":"39","author":"Wang","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"B350","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.celrep.2018.02.025","article-title":"Ubiquitination of MBNL1 Is required for its cytoplasmic localization and function in promoting neurite outgrowth.","volume":"22","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"B351","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/hmg\/ddx115","article-title":"Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.","volume":"26","author":"Wang","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B352","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.ymthe.2018.09.003","article-title":"Therapeutic genome editing for myotonic dystrophy type 1 using CRISPR\/Cas9.","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"B353","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2015.02.007","article-title":"Delivery of oligonucleotides with lipid nanoparticles.","volume":"87","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B354","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1128\/mcb.23.16.5489-5501.2003","article-title":"Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization.","volume":"23","author":"Wansink","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"B355","doi-asserted-by":"publisher","first-page":"18551","DOI":"10.1073\/pnas.0903234106","article-title":"Pentamidine reverses the splicing defects associated with myotonic dystrophy.","volume":"106","author":"Warf","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B356","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/WNL.0b013e3181d8c35f","article-title":"Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2.","volume":"74","author":"Weber","year":"2010","journal-title":"Neurology"},{"key":"B357","doi-asserted-by":"publisher","first-page":"e26555","DOI":"10.4161\/rdis.26555","article-title":"GSK3\u03b2 is a new therapeutic target for myotonic dystrophy type 1.","volume":"1","author":"Wei","year":"2013","journal-title":"Rare Dis."},{"key":"B358","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/neup.12721","article-title":"Human brain pathology in myotonic dystrophy type 1: a systematic review.","volume":"41","author":"Weijs","year":"2021","journal-title":"Neuropathology"},{"key":"B359","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","article-title":"Targeting nuclear RNA for in vivo correction of myotonic dystrophy.","volume":"488","author":"Wheeler","year":"2012","journal-title":"Nature"},{"key":"B360","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1173110","article-title":"Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.","volume":"325","author":"Wheeler","year":"2009","journal-title":"Science"},{"key":"B361","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/jnnp.2005.070763","article-title":"Facial emotion recognition in myotonic dystrophy type 1 correlates with CTG repeat expansion.","volume":"77","author":"Winblad","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B362","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1468-1331.2008.02217.x","article-title":"Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic dystrophy type 1.","volume":"15","author":"Winblad","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"B363","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/ene.13062","article-title":"Cognition in myotonic dystrophy type 1: a 5-year follow-up study.","volume":"23","author":"Winblad","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"B364","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4161\/rna.28799","article-title":"Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.","volume":"11","author":"Wojciechowska","year":"2014","journal-title":"RNA Biol."},{"key":"B365","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jocn.2019.07.029","article-title":"Differences in the pattern of cognitive impairments between juvenile and adult onset myotonic dystrophy type 1.","volume":"68","author":"Woo","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"B366","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s00415-012-6771-4","article-title":"Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1.","volume":"260","author":"Wozniak","year":"2013","journal-title":"J. Neurol."},{"key":"B367","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jns.2014.04.005","article-title":"Tractography reveals diffuse white matter abnormalities in myotonic dystrophy type 1.","volume":"341","author":"Wozniak","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B368","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nmd.2010.11.013","article-title":"White matter abnormalities and neurocognitive correlates in children and adolescents with myotonic dystrophy type 1: a diffusion tensor imaging study.","volume":"21","author":"Wozniak","year":"2011","journal-title":"Neuromusc. Disord."},{"key":"B369","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00418-015-1315-5","article-title":"Dynamic changes of nuclear RNA foci in proliferating DM1 cells.","volume":"143","author":"Xia","year":"2015","journal-title":"Histochem. Cell Biol."},{"key":"B370","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/stem.1970","article-title":"Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.","volume":"33","author":"Xia","year":"2015","journal-title":"Stem Cells"},{"key":"B371","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/cell.2012.0086","article-title":"Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.","volume":"15","author":"Xia","year":"2013","journal-title":"Cell. Reprogram."},{"key":"B372","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/hmg\/ddu617","article-title":"TWEAK\/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.","volume":"24","author":"Yadava","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B373","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/hmg\/ddaa060","article-title":"Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3\u2032UTR RNA.","volume":"29","author":"Yadava","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"B374","doi-asserted-by":"publisher","first-page":"26158","DOI":"10.1074\/jbc.M111.256446","article-title":"NDRG4 protein-deficient mice exhibit spatial learning deficits and vulnerabilities to cerebral ischemia.","volume":"286","author":"Yamamoto","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B375","doi-asserted-by":"publisher","first-page":"e26996","DOI":"10.1371\/journal.pone.0026996","article-title":"Granulovacuolar degenerations appear in relation to hippocampal phosphorylated tau accumulation in various neurodegenerative disorders.","volume":"6","author":"Yamazaki","year":"2011","journal-title":"PLoS One"},{"key":"B376","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.","volume":"17","author":"Yin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"B377","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.nicl.2016.04.012","article-title":"Relationship of white and gray matter abnormalities to clinical and genetic features in myotonic dystrophy type 1.","volume":"11","author":"Zanigni","year":"2016","journal-title":"Neuroimage Clin."},{"key":"B378","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/ijms17020182","article-title":"miR-30-5p regulates muscle differentiation and alternative splicing of muscle-related genes by targeting MBNL.","volume":"17","author":"Zhang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B379","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/hmg\/ddx190","article-title":"A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.","volume":"26","author":"Zhang","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B380","doi-asserted-by":"publisher","first-page":"594576","DOI":"10.3389\/fgene.2020.594576","article-title":"A CRISPR-Cas13a based strategy that tracks and degrades toxic RNA in myotonic dystrophy type 1.","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Genet."},{"key":"B381","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1017\/s1355838202027036","article-title":"Region-specific alternative splicing in the nervous system: implications for regulation by the RNA-binding protein NAPOR.","volume":"8","author":"Zhang","year":"2002","journal-title":"RNA"},{"key":"B382","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/mt.2013.251","article-title":"Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats.","volume":"22","author":"Zhang","year":"2014","journal-title":"Mol. Ther."},{"key":"B383","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.neubiorev.2011.12.011","article-title":"NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders.","volume":"36","author":"Zorumski","year":"2012","journal-title":"Neurosci. Biobehav. Rev."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.755392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T06:59:51Z","timestamp":1636959591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.755392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":383,"alternative-id":["10.3389\/fnagi.2021.755392"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.755392","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"article-number":"755392"}}